Genomic Testing in Squamous NSCLC

In this segment, the panel discusses the potential role of genomic testing and biomarker identification in advanced squamous non-small cell lung cancer (NSCLC), particularly as new therapeutic approaches emerge following immunotherapy. The experts consider whether dual immunotherapy approaches, including CTLA-4-directed strategies, may have a role in patients with low or negative PD-L1 expression. The discussion emphasizes that precision oncology has advanced further in nonsquamous NSCLC than in squamous disease and that the molecular biology of squamous NSCLC remains incompletely characterized. The panel encourages comprehensive genomic testing to identify potentially actionable alterations that might otherwise be missed, including less common genomic changes and RNA-based findings. Dr. Edward Kim highlights the importance of continuing to investigate the broader molecular landscape of squamous NSCLC, while Dr. Christian Rolfo discusses the potential value of identifying molecular signatures in addition to individual gene alterations. The panel concludes that improved molecular classification could help identify biologically distinct subgroups and support development of more personalized treatment strategies for squamous NSCLC.